Designs for Single- or Multiple-Agent Phase I Trials
From MaRDI portal
Recommendations
Cites work
- A Random Walk Rule for Phase I Clinical Trials
- Clinical Trials
- Confidence interval estimation subject to order restrictions
- Continual Reassessment Method: A Likelihood Approach
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- Dose finding using the biased coin up-and-down design and isotonic regression
- Dose-finding with two agents in phase I oncology trials
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
Cited in
(27)- A phase I dose-finding study based on polychotomous toxicity responses
- Adaptive clinical trial designs for phase I cancer studies
- Cumulative cohort design for dose-finding
- Continual reassessment method for partial ordering
- A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
- Dose-finding with two agents in phase I oncology trials
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates
- Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
- Two‐Dimensional Dose Finding in Discrete Dose Space
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials
- Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
- Applying the partial order continual reassessment method to high-dimensional treatment combinations
- A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies
- Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering
- Phase I/II adaptive design for drug combination oncology trials
- A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
- A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials
- Escalation with overdose control for phase I drug-combination trials
- A design for phase I trials in completely or partially ordered groups
- Designs for phase I trials in ordered groups
- Implementation of adaptive methods in early-phase clinical trials
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
This page was built for publication: Designs for Single- or Multiple-Agent Phase I Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3445286)
